Literature DB >> 31240431

Ibrutinib related bleeding complications in elderly patients with B cell malignancies.

Roberto Castelli1, Riccardo Schiavon2, Carlo Preti2, Giorgio Lambertenghi Deliliers3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31240431     DOI： 10.1007/s11239-019-01907-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  6 in total

1.  Platelet Counts and Risk of Major Bleeding With Ibrutinib.

Authors:  Marko Lucijanic; Marko Skelin
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2019-04-06

Review 2.  Management of adverse effects/toxicity of ibrutinib.

Authors:  Semra Paydas
Journal:  Crit Rev Oncol Hematol       Date:  2019-02-10       Impact factor: 6.312

3.  Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.

Authors:  Viola Denzinger; Kristina Busygina; Janina Jamasbi; Isabell Pekrul; Michael Spannagl; Christian Weber; Reinhard Lorenz; Wolfgang Siess
Journal:  Thromb Haemost       Date:  2019-01-27       Impact factor: 5.249

Review 4.  Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.

Authors:  Zhen Zhang; Daoguang Zhang; Yang Liu; Dezhi Yang; Fansheng Ran; Michael L Wang; Guisen Zhao
Journal:  Arch Pharm (Weinheim)       Date:  2018-05-09       Impact factor: 3.751

Review 5.  Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.

Authors:  Jingjing Wu; Mingzhi Zhang; Delong Liu
Journal:  Oncotarget       Date:  2017-01-24

6.  High incidence of atrial fibrillation in patients treated with ibrutinib.

Authors:  Florian Baptiste; Jennifer Cautela; Yan Ancedy; Noémie Resseguier; Thérèse Aurran; Laure Farnault; Marion Escudier; Chloé Ammar; Mélanie Gaubert; Charles Dolladille; Jeremie Barraud; Michael Peyrol; Ariel Cohen; Franck Paganelli; Joachim Alexandre; Stephane Ederhy; Franck Thuny
Journal:  Open Heart       Date:  2019-05-08
  6 in total
  1 in total

1.  Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study.

Authors:  William Alexander; Sarah Davis; Raj Ramakrishna; Arumugam Manoharan
Journal:  J Hematol       Date:  2020-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.